Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTABLISH-1: Tedizolid vs Linezolid in ABSSSI
NCT01170221Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of tedizolid in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Merck & Co.. Started Aug 2010; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT01170221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170221.